Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Virology   Volumes    Volume 1 
Targeting HIV-1 gp120 to the high affinity FC receptor (FCγRI, CD64) on myeloid antigen presenting cells: implications for enhancing vaccine responses
Alexandra L. Howell, Tara N. Thacker, Fang Li, Steve Fiering, Robert F. Graziano, Joel Goldstein, Michael W. Fanger
Pages: 61 - 70
Number of pages: 10
Current Topics in Virology
Volume 1 

Copyright © 1999 Research Trends. All rights reserved


We prepared a fusion protein containing a humanized monoclonal antibody (mAb), mAb H22, with specificity for the human high affinity Fc receptor for IgG (FcγRI, CD64), fused to HIV-1 gp120. This fusion protein construct was produced by joining the cDNA for the full length H22 heavy chain gene in frame to the cDNA for gp120. This construct, which also expressed a selectable marker, was stably transfected into a murine myeloma cell line that expressed the previously transfected H22 kappa light chain. The resulting fusion protein, (H22 x gp120), was secreted from the myeloma cell line and was purified by affinity chromatography. Flow cytometric analysis revealed that H22 x gp120 bound with high affinity via the Fab portion of H22 to CD64 expressed on monocytes and macrophages from both humans and human CD64- expressing transgenic mice. Western blot analysis revealed that the 390 kDa fusion protein reacted with both anti-human IgG and anti-gp120 mAbs. Incubation of a monocyte cell line with this fusion protein at 37°C resulted in internalization of the complex as determined by flow cytometric analysis. Immunization of human CD64 transgenic mice with the purified H22 x gp120 fusion protein induced higher titers of anti-gp120 serum antibodies compared to immunization of non-transgenic littermates. Targeting gp120 to CD64-expressing antigen presenting cells (APC) in vivo may augment immune responses and enhance protective immunity.

Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms